Massmutual Trust Co. FSB ADV Sells 46 Shares of Synopsys, Inc. (NASDAQ:SNPS)

Massmutual Trust Co. FSB ADV lessened its position in Synopsys, Inc. (NASDAQ:SNPSFree Report) by 7.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 535 shares of the semiconductor company’s stock after selling 46 shares during the period. Massmutual Trust Co. FSB ADV’s holdings in Synopsys were worth $275,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the company. Venturi Wealth Management LLC purchased a new position in shares of Synopsys during the third quarter valued at approximately $27,000. OFI Invest Asset Management purchased a new position in shares of Synopsys during the third quarter valued at approximately $26,000. Annis Gardner Whiting Capital Advisors LLC purchased a new position in shares of Synopsys during the third quarter valued at approximately $29,000. Freedom Wealth Alliance LLC purchased a new position in shares of Synopsys during the fourth quarter valued at approximately $26,000. Finally, VitalStone Financial LLC purchased a new stake in Synopsys during the first quarter valued at approximately $30,000. Institutional investors own 84.12% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have commented on the stock. Robert W. Baird upped their target price on shares of Synopsys from $624.00 to $640.00 and gave the company an “outperform” rating in a report on Thursday, February 22nd. Stifel Nicolaus reaffirmed a “buy” rating and set a $550.00 target price on shares of Synopsys in a report on Monday, November 27th. Needham & Company LLC reissued a “buy” rating and issued a $660.00 price objective on shares of Synopsys in a research note on Thursday, February 22nd. Wells Fargo & Company increased their price objective on shares of Synopsys from $620.00 to $630.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 13th. Finally, Rosenblatt Securities upped their target price on shares of Synopsys from $570.00 to $615.00 and gave the stock a “buy” rating in a research report on Tuesday, February 20th. One analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $594.60.

Get Our Latest Stock Report on Synopsys

Synopsys Stock Performance

NASDAQ SNPS opened at $550.03 on Friday. The company has a market capitalization of $83.90 billion, a price-to-earnings ratio of 60.58, a price-to-earnings-growth ratio of 3.16 and a beta of 1.07. The company’s 50-day simple moving average is $548.19 and its two-hundred day simple moving average is $515.26. Synopsys, Inc. has a one year low of $360.36 and a one year high of $629.38.

Synopsys (NASDAQ:SNPSGet Free Report) last posted its earnings results on Wednesday, February 21st. The semiconductor company reported $3.56 EPS for the quarter, beating analysts’ consensus estimates of $3.43 by $0.13. Synopsys had a net margin of 22.96% and a return on equity of 22.88%. The business had revenue of $1.65 billion for the quarter, compared to the consensus estimate of $1.65 billion. During the same quarter last year, the firm posted $1.75 EPS. The company’s revenue for the quarter was up 21.1% on a year-over-year basis. Equities analysts expect that Synopsys, Inc. will post 10.13 earnings per share for the current fiscal year.

Insider Activity

In other news, CEO Sassine Ghazi sold 10,294 shares of the firm’s stock in a transaction dated Friday, February 23rd. The shares were sold at an average price of $577.51, for a total value of $5,944,887.94. Following the sale, the chief executive officer now directly owns 61,863 shares in the company, valued at approximately $35,726,501.13. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In related news, Director Roy Vallee sold 10,000 shares of Synopsys stock in a transaction that occurred on Tuesday, February 27th. The shares were sold at an average price of $572.66, for a total value of $5,726,600.00. Following the completion of the sale, the director now directly owns 20,000 shares in the company, valued at approximately $11,453,200. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Sassine Ghazi sold 10,294 shares of Synopsys stock in a transaction that occurred on Friday, February 23rd. The stock was sold at an average price of $577.51, for a total transaction of $5,944,887.94. Following the completion of the sale, the chief executive officer now owns 61,863 shares of the company’s stock, valued at $35,726,501.13. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 36,586 shares of company stock worth $19,868,728. Corporate insiders own 0.66% of the company’s stock.

Synopsys Company Profile

(Free Report)

Synopsys, Inc provides electronic design automation software products used to design and test integrated circuits. It operates in three segments: Design Automation, Design IP, and Software Integrity. The company offers Digital and Custom IC Design solution that provides digital design implementation solutions; Verification solution that offers virtual prototyping, static and formal verification, simulation, emulation, field programmable gate array (FPGA)-based prototyping, and debug solutions; and FPGA design products that are programmed to perform specific functions.

Featured Articles

Want to see what other hedge funds are holding SNPS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Synopsys, Inc. (NASDAQ:SNPSFree Report).

Institutional Ownership by Quarter for Synopsys (NASDAQ:SNPS)

Receive News & Ratings for Synopsys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synopsys and related companies with MarketBeat.com's FREE daily email newsletter.